Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Sales | 8,656,000 | 8,213,000 | 8,430,000 | 8,292,000 | 8,617,000 |
| Cost of Goods | 1,612,000 | 1,593,000 | 1,482,000 | 1,339,000 | 1,759,000 |
| Gross Profit | 7,044,000 | 6,620,000 | 6,948,000 | 6,953,000 | 6,858,000 |
| Operating Expenses | 4,877,000 | 2,358,000 | 3,983,000 | 3,552,000 | 4,029,000 |
| Operating Income | 2,167,000 | 4,262,000 | 2,965,000 | 3,401,000 | 2,829,000 |
| Interest Expense | -177,000 | 246,000 | 243,000 | 250,000 | 1,033,000 |
| Other Income | -376,000 | 153,000 | 136,000 | 137,000 | 487,000 |
| Pre-tax Income | 1,968,000 | 4,169,000 | 2,858,000 | 3,288,000 | 2,283,000 |
| Income Tax | 541,000 | 684,000 | 735,000 | 373,000 | 651,000 |
| Net Income Continuous | 1,493,000 | 3,485,000 | 2,123,000 | 2,915,000 | 1,632,000 |
| Minority Interests | 7,000 | 8,000 | 10,000 | 8,000 | N/A |
| Net Income | $1,493,000 | $3,477,000 | $2,113,000 | $2,907,000 | $1,632,000 |
| EPS Basic Total Ops | 0.58 | 1.28 | 0.77 | 1.04 | 0.58 |
| EPS Basic Continuous Ops | 0.57 | 1.29 | 0.77 | 1.04 | 0.58 |
| EPS Diluted Total Ops | 0.58 | 1.27 | 0.77 | 1.04 | 0.57 |
| EPS Diluted Continuous Ops | 0.57 | 1.28 | 0.77 | 1.04 | 0.57 |
| EBITDA(a) | $3,137,000 | $4,805,000 | $3,476,000 | $3,927,000 | $4,136,000 |